Tobam Sells 24,690 Shares of DaVita Inc. (NYSE:DVA)

Tobam reduced its position in DaVita Inc. (NYSE:DVA - Free Report) by 15.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 136,223 shares of the company's stock after selling 24,690 shares during the period. Tobam owned about 0.15% of DaVita worth $14,271,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of DVA. Resources Management Corp CT ADV increased its position in DaVita by 5,900.0% in the 2nd quarter. Resources Management Corp CT ADV now owns 300 shares of the company's stock worth $30,000 after purchasing an additional 295 shares during the last quarter. Harbor Investment Advisory LLC bought a new stake in shares of DaVita during the 3rd quarter worth about $34,000. Parkside Financial Bank & Trust boosted its stake in shares of DaVita by 88.6% during the 1st quarter. Parkside Financial Bank & Trust now owns 313 shares of the company's stock worth $35,000 after acquiring an additional 147 shares in the last quarter. Hanseatic Management Services Inc. bought a new stake in shares of DaVita during the 3rd quarter worth about $36,000. Finally, FinTrust Capital Advisors LLC boosted its stake in shares of DaVita by 242.3% during the 3rd quarter. FinTrust Capital Advisors LLC now owns 712 shares of the company's stock worth $67,000 after acquiring an additional 504 shares in the last quarter. 90.12% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, insider Kathleen Alyce Waters sold 11,285 shares of the stock in a transaction that occurred on Wednesday, February 21st. The stock was sold at an average price of $120.73, for a total value of $1,362,438.05. Following the completion of the transaction, the insider now directly owns 81,297 shares of the company's stock, valued at approximately $9,814,986.81. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other news, CEO Javier Rodriguez sold 67,603 shares of the stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $126.11, for a total value of $8,525,414.33. Following the completion of the transaction, the chief executive officer now directly owns 488,697 shares of the company's stock, valued at approximately $61,629,578.67. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Kathleen Alyce Waters sold 11,285 shares of the stock in a transaction that occurred on Wednesday, February 21st. The stock was sold at an average price of $120.73, for a total value of $1,362,438.05. Following the completion of the transaction, the insider now directly owns 81,297 shares of the company's stock, valued at $9,814,986.81. The disclosure for this sale can be found here. In the last quarter, insiders sold 134,540 shares of company stock worth $16,551,071. 1.40% of the stock is currently owned by company insiders.

DaVita Stock Performance

NYSE:DVA traded up $0.33 during mid-day trading on Tuesday, hitting $134.06. 310,540 shares of the company's stock traded hands, compared to its average volume of 856,490. The firm has a 50 day moving average of $127.71 and a two-hundred day moving average of $107.32. The company has a current ratio of 1.19, a quick ratio of 1.13 and a debt-to-equity ratio of 6.65. DaVita Inc. has a 12 month low of $71.51 and a 12 month high of $141.54. The firm has a market capitalization of $11.76 billion, a price-to-earnings ratio of 18.12, a price-to-earnings-growth ratio of 1.19 and a beta of 1.04.

DaVita (NYSE:DVA - Get Free Report) last announced its quarterly earnings data on Tuesday, February 13th. The company reported $1.87 EPS for the quarter, topping analysts' consensus estimates of $1.53 by $0.34. DaVita had a return on equity of 64.42% and a net margin of 5.70%. The company had revenue of $3.15 billion during the quarter, compared to the consensus estimate of $3.01 billion. During the same quarter last year, the company earned $1.11 EPS. The company's quarterly revenue was up 7.8% on a year-over-year basis. On average, equities analysts forecast that DaVita Inc. will post 9.23 earnings per share for the current fiscal year.

Analysts Set New Price Targets

DVA has been the subject of several recent analyst reports. UBS Group upped their price target on DaVita from $113.00 to $134.00 and gave the stock a "buy" rating in a research note on Wednesday, February 14th. StockNews.com upgraded DaVita from a "buy" rating to a "strong-buy" rating in a research note on Monday. Truist Financial increased their target price on DaVita from $130.00 to $135.00 and gave the company a "hold" rating in a research note on Tuesday, February 20th. TheStreet upgraded DaVita from a "c+" rating to a "b-" rating in a research note on Wednesday, February 7th. Finally, Barclays started coverage on DaVita in a research note on Wednesday, March 6th. They set an "equal weight" rating and a $133.00 target price for the company. Two investment analysts have rated the stock with a hold rating, one has issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, DaVita currently has an average rating of "Moderate Buy" and an average price target of $118.50.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.